A 52-year-old man from Delhi presents with a 3-month history of painless lymphadenopathy involving the neck, axilla, and groin. On examination, he has firm, mobile, non-tender lymph nodes. Laboratory investigations show hemoglobin 11.2 g/dL, WBC 7,200/μL, and platelets 180,000/μL. LDH is elevated at 580 U/L. A lymph node biopsy is performed and histopathology reveals diffuse proliferation of small lymphocytes with scant cytoplasm, coexpressing CD5 and CD19. Flow cytometry confirms CD5+, CD19+, CD23+ B cells. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has histopathologically and immunophenotypically confirmed **Chronic Lymphocytic Leukemia (CLL)** or small lymphocytic lymphoma (SLL) — the tissue manifestation of the same disease. The CD5+, CD19+, CD23+ phenotype is pathognomonic. ## Why Staging Is the Next Step **Key Point:** Before initiating any treatment in newly diagnosed lymphoma, complete staging is mandatory to determine: - Extent of disease (Ann Arbor stage) - Prognostic factors (LDH, β~2~-microglobulin, bone marrow involvement) - Presence of cytopenias attributable to marrow infiltration vs. autoimmune phenomena - Fitness for treatment **High-Yield:** In CLL/SLL, staging investigations include: 1. **CT chest/abdomen/pelvis** — assess nodal burden, splenomegaly, hepatomegaly 2. **Bone marrow biopsy** — determine marrow involvement (prognostic, informs treatment intensity) 3. **Serum β~2~-microglobulin and LDH** — prognostic markers 4. **Cytogenetics/FISH** — del(17p), del(11q), trisomy 12, unmutated IGHV (guide intensity of therapy) 5. **TP53 mutation status** — increasingly important for treatment selection ## Why Other Options Are Premature **Clinical Pearl:** Although this patient is asymptomatic with early-stage disease, **staging must precede the decision between observation and treatment**. Staging may reveal advanced disease (stage III–IV), marrow failure, or high-risk cytogenetics that mandate immediate treatment despite lack of symptoms. **Mnemonic: STAG** — **S**taging, **T**herapy selection, **A**ssess prognostic factors, **G**uide intensity. | Step | Rationale | |------|----------| | Staging first | Defines extent, prognosis, treatment eligibility | | Then risk stratification | Determines watch-and-wait vs. immediate therapy | | Then treatment selection | Based on stage, cytogenetics, comorbidities, patient age | **Warning:** Initiating CHOP or rituximab without staging is a common exam trap — it commits the patient to treatment without knowing if they truly need it or what the optimal regimen is. ## Treatment Decisions Post-Staging Once staging is complete: - **Early-stage (I–II), asymptomatic, no adverse prognostic factors** → Watch and wait (observation) - **Advanced stage (III–IV) OR symptomatic OR adverse prognostics (del 17p, unmutated IGHV, TP53 mutation)** → Immediate therapy (venetoclax + obinutuzumab, or FCR, or BTK inhibitors depending on fitness and cytogenetics) [cite:Robbins 10e Ch 20; Harrison 21e Ch 104]